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Abstract
The annually reformulated trivalent inactivated influenza vaccine (TIV) includes both influenza A/subtypes (H3N2 and H1N1)
but only one of two influenza B/lineages (Yamagata or Victoria). In a recent series of clinical trials to evaluate prime-boost
response across influenza B/lineages, influenza-naı ¨ve infants and toddlers originally primed with two doses of 2008–09 B/
Yamagata-containing TIV were assessed after two doses of B/Victoria-containing TIV administered in the subsequent 2009–
10 and 2010–11 seasons. In these children, the Victoria-containing vaccines strongly recalled antibody to the initiating B/
Yamagata antigen but induced only low B/Victoria antibody responses. To further evaluate this unexpected pattern of cross-
lineage vaccine responses, we conducted additional immunogenicity assessment in mice. In the current study, mice were
primed with two doses of 2008–09 Yamagata-containing TIV and subsequently boosted with two doses of 2010–11 Victoria-
containing TIV (Group-Yam/Vic). With the same vaccines, we also assessed the reverse order of two-dose Victoria followed
by two-dose Yamagata immunization (Group-Vic/Yam). The Group-Yam/Vic mice showed strong homologous responses to
Yamagata antigen. However, as previously reported in children, subsequent doses of Victoria antigen substantially boosted
Yamagata but induced only low antibody response to the immunizing Victoria component. The reverse order of Group-Vic/
Yam mice also showed low homologous responses to Victoria but subsequent heterologous immunization with even a
single dose of Yamagata antigen induced substantial boost response to both lineages. For influenza A/H3N2, homologous
responses were comparably robust for the differing TIV variants and even a single follow-up dose of the heterologous strain,
regardless of vaccine sequence, substantially boosted antibody to both strains. For H1N1, two doses of 2008–09 seasonal
antigen significantly blunted response to two doses of the 2010–11 pandemic H1N1 antigen. Immunologic interactions
between influenza viruses considered antigenically distant and in particular the cross-lineage influenza B and dominant
Yamagata boost responses we have observed in both human and animal studies warrant further evaluation.
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Introduction
Since 1980, two lineages of influenza B viruses, represented by
B/Yamagata/16/1988-like and B/Victoria/2/1987-like strains,
have been recognized based on their antigenically distinct
hemagglutinin (HA) surface proteins [1]. After an absence of
more than ten years in North America, the Victoria lineage re-
appeared in 2001 and at the end of 2002, a reassortment event
occurred such that all type B viruses from 2003 onward bear the
Yamagata neuraminidase (NA) [2]. Strains descended from both
lineages variously contribute to annual influenza activity.
The annually reformulated trivalent inactivated influenza
vaccine (TIV) contains both influenza A/subtypes (A/H3N2 and
A/H1N1) but only one of the two major influenza B/lineages
(Victoria or Yamagata). Young children are less likely to have had
priming experience with influenza, and it is thus recommended
that previously unvaccinated children ,9 years of age receive two
TIV doses for their initiating series, and a single dose annually
thereafter [3]. This recommendation assumes effective prime-
boost across related antigenic variants within a given influenza A/
subtype, but does not account for major change in the influenza
B/lineage from year-to-year.
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38929In a recent series of clinical trials to assess prime-boost response
across influenza B/lineages, we followed children enrolled as
influenza-naı ¨ve infants and toddlers given two doses of the 2008–
09 Vaxigrip split TIV (Sanofi Pasteur; Lyon, France) containing
influenza B/Yamagata antigen [4]. The following year, a subset of
these children was administered, per recommendation, a single
dose of the 2009–10 Vaxigrip containing B/Victoria-lineage
antigen [5]. A single dose of the 2009–10 Victoria antigen strongly
recalled response to the 2008–09 priming Yamagata antigen, but
titres to the immunizing Victoria antigen remained low. To assess
whether another dose might recuperate a better Victoria response,
a further subset was enrolled the next season to receive a single
dose, per recommendation, of the same Victoria antigen in the
2010–11 Vaxigrip [3,5]. That further dose, however, did not well
improve the Victoria response, but again boosted titres to the
Yamagata priming antigen.
It is unclear whether the cross-lineage influenza B results we
observed in young children were specific to a particular product,
antigen, or sequence of influenza B/lineage prime-boost. Few
prior studies have specifically assessed cross-lineage influenza B
vaccine responses [6–8] and additional opportunity to assess this
has been limited to date by use of the same Victoria lineage
antigen in the 2011–12 TIV. To further explore the unexpected
cross-lineage influenza B responses we observed in naı ¨ve children,
we conducted an animal study in which influenza-naı ¨ve mice were
immunized with a different manufacturer’s TIV products from the
same seasons, including the same Yamagata-Victoria sequence but
also the reverse order of Victoria-Yamagata vaccine administra-
tion.
Methods
Ethics Statement
Animal procedures were approved by the Institutional Animal
Care Committee at Laval University according to the guidelines of
the Canadian Council on Animal Care.
Mouse Immunization and Follow-Up
TIV immunogenicity was assessed in two groups of fifty 6–8-
week-old female BALB/c mice (Charles River). All immunizations
and serologic testing were conducted in blinded fashion. Animals
were housed five per HEPA-filtered cage. Food and water were
available ad libitum.
Mice belonging to Group-Yam/Vic received two immunizations
with 2008–09 TIV (Yamagata lineage antigen) followed by two
immunizations with 2010–11 TIV (Victoria lineage antigen). On
day 0, these mice were immunized intramuscularly with 100 mlo fa
single lot of 2008–09 Fluviral non-adjuvanted split TIV (Glaxo-
SmithKline; Laval, Quebec, Canada) containing 3.0 mg HA [9] of
each antigen i.e. B/Florida/4/2006(Yamagata)-like, A/Uruguay/
716/2007(NYMC X-175C)(H3N2) (antigenically-equivalent to the
WHO-recommendedA/Brisbane/10/2007(H3N2)strain),andA/
Brisbane/59/2007(H1N1)-like [10,11]. A second immunization
was repeated on day 14 with the same formulation. Two months
later,anotherroundoftwo14-day-spacedimmunizationswasgiven
in the same mice with a single lot of the 2010–11 Fluviral non-
adjuvanted split TIV containing three different antigens: B/
Brisbane/60/2008(Victoria)-like (a major influenza B lineage-level
change compared withthe 2008–09component), A/Victoria/210/
2009(NYMCX-187)(H3N2)(antigenically-equivalenttotheWHO-
recommendedA/Perth/16/2009(H3N2)strain,itselfadriftvariant
compared with the 2008–09 component), and A/California/7/
2009(H1N1)-like (i.e. A/(H1N1)pdm09, a major H1N1 pandemic
change compared with the 2008–09 seasonal component) [11,12].
Supporting Information provides detail on the relatedness of 2008–
09and2010–11TIVandstudyantigens(TableS1,TableS2,Table
S3, Table S4).
Group-Vic/Yam mice were immunized on the same dates in
the same way using the same vaccine lots but in reverse sequence
i.e. two immunizations with 2010–11 TIV (Victoria lineage
antigen) followed by two immunizations with 2008–09 TIV
(Yamagata lineage antigen).
All immunizations occurred between end-May and mid-August,
2011. Single radial immuno-diffusion (SRID) testing at .2 years
post-expiry of the 2008–09 TIV lot that was used confirmed that
all three strains still met standard potency requirements [Personal
Communication, Dr. Rajesh Gupta, Center for Biologics Evalu-
ation and Research, US Food and Drug Administration]. The
2010–11 TIV was administered within specified vaccine expiry.
Blood was collected prior to each immunization by cheek vein
and two weeks after final immunization by cardiac puncture. Due
to small blood volume, serum samples from the five mice per cage
were pooled, rendering an effective sample size of 10 per group
per time point.
Serologic Assays
Sera were tested in duplicate for antibodies to non-inactivated
viruses by hemagglutination inhibition (HI) assay for influenza A
and B and additionally by microneutralization (MN) assay for
influenza B according to methods described below. Test viruses
were supplied by GlaxoSmithKline (GlaxoSmithKline; Laval,
Quebec, Canada) with the exception of the A/California/7/
2009(H1N1)-like virus, for which a Quebec isolate was used
(GenBank accession numbers FN434457-FN434464). For the
WHO-recommended A/Brisbane/10/2007(H3N2)-like vaccine
component of the 2008–09 TIV, A/Uruguay/716/2007(H3N2)
was used as the antigenically equivalent test strain (‘‘Brisba-
ne(H3N2)-like’’). Titres ,10 were assigned a value of 5. Where
there was discordance in duplicate assay results, the lower value
was recorded. Primary antibody endpoints included group
geometric mean titres (GMTs), post- versus pre-immunization
GMT ratio (GMTR) and proportion with titre $40.
Hemagglutination inhibition (HI) assay. HI assay was
based on WHO protocol with modification as detailed below
[13,14]. Non-specific inhibitors were removed from serum by
overnight treatment with receptor destroying enzyme (Denka
Seiken, Tokyo, Japan). Physiologic saline solution was then added
to achieve a 1:10 dilution, followed by incubation with packed
turkey red blood cells (TRBC) or guinea pig red blood cells
(GPRBC) at 4uC for 60 min to remove non-specific agglutinins
(Lampire Biological Laboratories Inc., Pipersville, PA). Treated
serum was serially diluted in 25 ml of PBS and then mixed with an
equal volume of PBS containing 4 hemagglutinin units of the
different influenza A or B viruses. After 30 min of incubation at
room temperature, 50 ml of 0.7% TRBC solution was added to the
mixture then incubated for 30–60 min before evaluation of
hemagglutination. For A/Brisbane/59/2007(H1N1) HI was also
conducted with 1.2% GPRBC. The HI titer was recorded as the
reciprocal of the last dilution that inhibited hemagglutination.
Microneutralization. Sera were first inactivated for 30 min
at 56uC. Beginning with a 1:10 dilution two-fold serial dilutions of
sera were mixed with equal volume of medium (Dulbecco’s
Modification of Eagle’s Medium with L-glutamine, 4.5 g/L
glucose and sodium pyruvate) containing 100 TCID50 of
influenza B viruses. After a 2-h incubation at 37uCi n5 %C O 2
humidified atmosphere, the residual infectivity of the virus-serum
mixture (50 ml) was determined by infecting confluent MDCK
cells. Neutralizing antibody titers were defined as the reciprocal of
Heterologous Influenza A/B Immunogenicity in Mice
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infectivity of the virus as determined by the absence of cytopathic
effect at day 4 post-infection [15].
Gene Sequencing
To assist in the interpretation of immunogenicity findings,
surface protein sequences of influenza B study viruses were
compared against representative B/Yamagata/16/1988 and B/
Victoria/2/1987 lineage viruses; relevant influenza A and B
vaccine strains for comparison were also downloaded from NCBI’s
Influenza Virus Resource [16]. Antigenic regions for influenza B
have not been defined, therefore pairwise identities were
calculated over the HA1 domain of hemagglutinin and the full-
length neuraminidase for both influenza A and B vaccine and
study strains. Pairwise identities were calculated from alignments
generated with MAFFT [17].
Results
Influenza B
Group-Yam/Vic animals confirmed the previous pattern of
influenza B responses we first reported in children (Table 1) [4,5].
The Yamagata antigen induced strong antibody response to the
homologous virus, but little cross-reactive antibody to the Victoria
antigen. A single follow-up dose with Victoria antigen substantially
boosted antibody to the priming Yamagata lineage but titres to the
immunizing Victoria antigen remained significantly lower even
with two doses.
Group-Vic/Yam animals provide additional insight not avail-
able in the earlier pediatric trials (Table 1) [4,5]. After two
initiating doses, the homologous response to the Victoria antigen
in the Vic/Yam animals was low. Follow-up immunization with
Yamagata antigen, however, revealed the Victoria antigen to have
nevertheless been an effective priming immunogen, even cross-
lineage: with a single dose of Yamagata antigen, titres were
significantly raised to both lineages. Titres to Yamagata signifi-
cantly exceeded those following two homologous priming
Yamagata doses in Group-Yam/Vic mice and Victoria titres
were also significantly raised 4-7-fold.
Overall, there was dominant Yamagata boost response regard-
less of the lineage used for the initiating series or subsequent
boosting. The same patterns were observed by HI and MN, but
were more pronounced by HI (Table 1).
Influenza A
For H3N2, homologous responses were comparably robust for
the 2008–09 and 2010–11 TIV antigens (Table 2). Cross-reactive
heterotypic responses were low. However, even a single follow-up
dose of the heterologous strain, regardless of the sequence of
vaccine receipt, elevated the antibody response to both strains.
For H1N1 (Table 3), the 2008–09 A/Brisbane/59/2007 antigen
induced little antibody response; the same antigen was also cited in this
manufacturer’s product monograph for its failure to meet immuno-
genicity criteria among older adults in pre-season trials conducted for
2009–10 [18]. Repeat HI assay using GPRBC did not change these
findings in mice. Despite this, response to two-dose A/California/07/
2009(H1N1) immunization was significantly blunted when preceded
by A/Brisbane/59/2007 priming compared to two-dose A/Califor-
nia/07/2009(H1N1) immunization of naı ¨ve animals.
Gene Sequencing
The Yamagata/16/1988 and Victoria/2/1987 reference strains
showed 92.8% cross-lineage pairwise identities in their HA1,
whereas descendant strains showed reduced cross-lineage pairwise
identity (average 90.2% ) (Table S1). Although these cross-lineage
identities are less than the pairwise identities observed between
variants within an influenza B/lineage or A/H3N2 subtype
($96%), they are greater than the pairwise identities across the
most recent seasonal and pandemic H1N1 strains (,72%) and far
exceed the pairwise identity across influenza A/H3 and A/H1
subtypes (,35%) (Tables S1, Table S3).
NA identities were more conserved across influenza B/lineages
(Table S2). Despite 2002 reassortment, identity was greater between
Yamagata/16/1988 and Victoria/2/1987 reference strains (96.8%)
than cross-lineage between their most recent descendants (95.5%),
suggesting possible drift in the NA. Influenza B cross-lineage identities
for NA appear greater than the pairwise identities observed across the
most recent seasonal and pandemic N1 strains (,81%) and also far
exceed the pairwise identity across the most recent influenza A/N2 and
A/N1 subtype strains (,42%) (Tables S2, S4).
Discussion
Influenza B contributes significantly to winter respiratory illness,
especially among children, causing seasonal epidemics every 2–4
years [19]. Given recognized variability in vaccine protection and
proposals for a revised quadrivalent formulation, better under-
standing of influenza B vaccine responses and possible immuno-
logic interactions is important [19].
In the current study, we confirmed dominant Yamagata
responses reported for the first time during a recent series of
clinical trials in which naı ¨ve children were initiated per
recommendation with two doses of Yamagata antigen and boosted
with Victoria antigen [4,5]. Here we observed the same effect in
naı ¨ve adult mice using another manufacturer’s TIV products from
the same seasons. To assess the directionality of this pattern of
cross-lineage prime-boost responses, we additionally included mice
that were instead initiated with Victoria and subsequently boosted
with Yamagata lineage antigen. This showed that regardless of
priming lineage, the boost response to Yamagata was persistently
dominant. The Victoria antigen induced weaker homologous
response but was still an effective immunogen for single-dose cross-
lineage Yamagata boost. Conversely, the Yamagata antigen
induced robust homologous prime-boost responses, but subse-
quent response to Victoria antigen remained low.
Although the antigenic distance between influenza B/lineages
has generally been compared to that across influenza A/subtypes
[19], our HA1 sequence analysis showed almost three-fold higher
overall pairwise identity between B/Yamagata and B/Victoria than
across A/H3 and A/H1 subtypes (Tables S1 and S3). These may be
lower in specific antibody-binding sites, but cannot be determined
without influenza B-specific HA epitope maps. Our immunogenic-
ity findings also suggest some degree of cross-lineage immune
recognition, since B/Victoria antigen both effectively primed for
Yamagata and substantially recalled priming Yamagata responses.
In an earlier study, Levandowski also showed this cross-lineage
immune recognition, with two-dose Yamagata immunization
inducing substantial Yamagata responses and recalling Victoria
responses in previously Victoria-primed but not unprimed children
[6]. As in the current mouse study and using the same 2010–11
TIV, Gilca et al have also recently reported reduced immunoge-
nicity for the B/Victoria antigen in young Quebec children
previously primed with Yamagata antigen [20]. Similarly, among
Canadian children 12–59 months of age immunized with the 2009–
10 adjuvanted pandemic H1N1 vaccine, Langley et al have
reported significantly lower 2010–11 B/Victoria (but not lower
influenza A) responses in those who had also previously received the
2009–10 TIV [21]. Although the same B/Victoria antigen was
Heterologous Influenza A/B Immunogenicity in Mice
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report immunization history prior to 2009: it is therefore unclear to
what extent the possibly correlated receipt of 2008–09 or earlier
Yamagata-containing TIV may have also been influential [21].
Among adults, the B/Victoria antigen has also been reported as
significantly less immunogenic than influenza A components for
both the 2009–10 and 2010–11 TIV but analysis based on prime-
boost history is yet more complex and challenging for adults and
was not presented in these publications [22,23].
The underlying immunologic mechanism for the Yamagata
dominance we report, if real, warrants better understanding. Such
one-way cross-lineage cross-reactivity has also been highlighted by the
World Health Organization [14], although reasons for this have not
been elaborated. In the current study, Group-Yam/Vic mice might be
consistent with original antigenic sin, whereby antibody to priming
antigens is preferentially recalled at the expense of response to
subsequent related-but-distinct viruses [24–26]. However, the Group-
Vic/Yam mice suggest this imprinting does not apply in reverse:
Yamagata boost was able to overcome the Victoria priming
experience. For influenza A, intravirionic antigenic competition is
thought to exist between HA and NA proteins recognized as an
assembly by cells of the immune system [27]. HA immune-dominance
is thought to suppress NA responses under most conditions. However,
in a process termed ‘‘reverse antigen competition’’, the relative
importance of the NA immune response is increased, with anti-NA
suppressing HA response in NA-primed populations lacking HA cross-
reactive antibodies [27]. Closer cross-lineage homology for NA might
signal its more prominent role and account for the Yamagata antigen’s
dominance among Group-Yam/Vic responses when boosted with
Victoria HA. A greater role for anti-NA antibody may also explain
diversity in the NA protein. This hypothesis, however, is weakened by
uncertainty in the NA content of TIV, the uncertain role of NA-
antibody in influencing HI results and the greater difficulty in
reconciling with the Group-Vic/Yam findings. We did not assess anti-
NA responses but these may also be of follow-up interest. Neither
original antigenic sin nor reverse antigenic dominance have been
specifically studied for influenza B. In fact, studies of influenza B
immune responses are lacking generally. Other cross-lineage interac-
tions, overriding epitope-specific effects, immunologic tolerance,
suppression or other mechanisms may be involved [28]. Whatever
the mechanism invoked, it must be able to account for the hierarchical
responses we observed based on the sequence of administration for
some but not all antigens, heterotypic in one direction but not the
other. Similarly, the mechanism for diminished A/(H1N1)pdm09
responses when preceded by antigenically distant seasonal H1N1
priming is unclear. Blunting of A/(H1N1)pdm09 vaccine-induced
Table 2. Cross-strain influenza A(H3N2) antibody responses measured by HI assay.*
GROUP Yam/Vic: 2008–09/2010–11 TIV
Sequence Initiating antigen Boosting antigen
Test Antigen Brisbane-like Brisbane-like Perth Perth
Brisbane-like Pre- vaccination Post 2008–09 TIV 1
a Post 2008–09 TIV 2
b Post 2010–11 TIV 1
a Post 2010–11 TIV 2
a
GMT (95%CI) 5.0 32.5 (25.6–41.3) 130 (102.3–165.1) 1194.3 (729.4–1955.5) 1114.3 (667.7–1859.6)
GMTR
{ 6.50 26.0 9.19 0.93
% titre $40 (95%CI) 0 70 (35–100) 100 100 100
Perth
GMT (95%CI) 5.0 5.0 6.2 (4.4–8.6) 557.2 (302.9–1024.9) 519.8 (324.8–832.1)
GMTR
{ 1 1.24 89.87 0.93
% titre $40 (95%CI) 0 0 0 100 100
GROUP Vic/Yam: 2010–11/2008–09 TIV
Sequence
Initiating antigen Boosting antigen
Test antigen Perth Perth Brisbane-like Brisbane-like
Brisbane-like Pre- vaccination Post 2010–11 TIV 1
a Post 2010–11 TIV 2
b Post 2008–09 TIV 1
a Post 2008–09 TIV 2
a
GMT (95%CI) 5.0 5.0 6.2 (4.8–7.8) 343 (189.4–621) 452.5 (296.9–689.7)
GMTR
{ 1.00 1.24 55.32 1.32
% titre $40 (95%CI) 0 0 0 100 100
Perth
GMT (95%CI) 5.0 11.5 (6.5–20.2) 183.8 (134.3–251.5) 787.9 (523.8–1185.2) 844.5 (597.1–1194.4)
GMTR
{ 2.3 36.76 4.29 1.07
% titre $40 (95%CI) 0 20 (0 – 50) 100 100 100
HI=hemagglutination inhibition; TIV = trivalent inactivated influenza vaccine. Note that undetectable titres ,10 were assigned a value of 5.
*Unit of analysis pooled sera from 5 mice, thus 10 pools from 50 mice were available for this experiment.
aMeasured two weeks after specified TIV dose;
bMeasured two months after specified TIV dose.
{Compared to pre-immunization for priming antigens; compared to immediately preceding titre for boosting antigens.
Brisbane-like = A/Uruguay/716/2007(NYMC 175C)(H3N2) considered antigenically equivalent to the WHO recommended A/Brisbane/10/2007(H3N2) component of the
2008–09 northern hemisphere TIV.
Perth = A/Perth/16/2009(H3N2)-like, component of the northern hemisphere 2010–11 TIV.
doi:10.1371/journal.pone.0038929.t002
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also been reported in human immunogenicity trials [29–34], shown
here also in mice despite absence of seasonal H1 antibody induction.
Conversely, pandemic H1N1 immunization has been observed to
boost pre-existing heterosubtypic neutralizing antibody levels [35]. Our
study further exposes possible immunologic interactions between
related but antigenically distant influenza viruses, including cross-
lineage influenza B effects, but it cannot elucidate the mechanisms.
Further evaluation is needed.
Limitations of this study warrant consideration. It is recognized
that mice do not necessarily represent human immune responses
in quantity, quality or kinetics. In the current study, spacing
between prime-boost vaccine doses was two weeks and between
seasonal formulations was two months. This was intentionally
shortened from the four-week prime-boost interval and annual
administration recommended for children to reflect the shortened
lifespan and time scale of mice relative to humans. The published
literature references a range of two-dose influenza vaccine spacing
in mice including the use of 2[36–39], 3[37,40–42] or 4[43–45]
week intervals. Since in this study we used the same schedule
regardless of antigen or its order of administration, the chosen
interval between prime-boost doses while potentially influential is
unlikely to explain our differential findings on that basis. Although
the 2008–09 TIV was nearly 2 years expired when used, we
elicited excellent Yamagata and H3N2 responses; reduced H1N1
responses were in keeping with human immunogenicity findings
also reported with that manufacturer’s antigen [18]. Furthermore,
standard SRID testing confirmed ongoing potency of the vaccine
lot that was used. Differences in timing between the first (2 month)
versus final (2 week) two-dose blood draw for the initiating versus
boosting series should be taken into account–2 weeks should be
sufficient for boost response but the possibility that final antibody
rise had not yet been achieved or conversely that waning had
occurred over the 2 month interval cannot be ruled out. Again,
this is unlikely to explain differential findings by antigen since the
same schedule of blood draw was followed for each immunization
series. To ensure sufficient sera for assessment across multiple
assays and antigens, we pooled from several mice, potentially
masking underlying variability. Differences in laboratory protocols
and a degree of error in antibody assays are acknowledged [46,47].
We did not include ether-treatment of the influenza B antigens for
HI assay, an approach thought to increase sensitivity but decrease
specificity of influenza B HI assay results [48,49]. However, ether
treatment did not alter the overall pattern observed in the earlier
pediatric study [5] and trends were consistent by HI and MN in
both studies. We emphasize observed trends over absolute values.
We cannot rule out that our observations are particular to the
specific influenza B strains used in both the pediatric and mice
Table 3. Cross-strain influenza A(H1N1) antibody responses measured by HI assay.*
GROUP Yam/Vic: 2008–09/2010–11 TIV
Sequence Initiating antigen Boosting antigen
Test Antigen Brisbane Brisbane California California
Brisbane Pre- vaccination Post 2008–09 TIV 1
a Post 2008–09 TIV 2
b Post 2010–11 TIV 1
a Post 2010–11 TIV 2
a
GMT (95%CI) 5.0 5.0 10 (6.7–15) 13.2 (9.3–18.7) 8.1 (5.8–11.4)
GMTR
{ 1.00 2.00 1.32 0.61
% titre $40 (95%CI) 0 0 0 10 (0–33) 0
California
GMT (95%CI) 5.0 5.0 5.0 5.0 16.2 (8–32.8)
GMTR
{ 1.00 1.00 1.00 3.24
% titre $40 (95%CI) 0 0 0 0 30 (0–65)
GROUP Vic/Yam: 2010–11/2008–09 TIV
Sequence
Inititating antigen Boosting antigen
Test antigen California California Brisbane Brisbane
Brisbane Pre- vaccination Post 2010–11 TIV 1
a Post 2010–11 TIV 2
b Post 2008–09 TIV 1
a Post 2008–09 TIV 2
a
GMT (95%CI) 5.0 5.0 5.0 5.0 5.4 (4.6–6.3)
GMTR
{ 1.00 1.00 1.00 1.08
% titre $40 (95%CI) 0 0 0 0 0
California
GMT (95%CI) 5.0 5.7 (4.7–7.1) 74.6 (56.3–98.9) 74.6 (63.8–87.3) 45.9 (33.6–62.9)
GMTR
{ 1.14 14.92 1.00 0.62
% titre $40 (95%CI) 0 0 100 100 90 (67–100)
HI = hemagglutination inhibition; TIV = trivalent inactivated influenza vaccine. Note that undetectable titres ,10 were assigned a value of 5.
*Unit of analysis pooled sera from 5 mice, thus 10 pools from 50 mice were available for this experiment.
aMeasured two weeks after specified TIV dose;
bMeasured two months after specified TIV dose.
{Compared to pre-immunization for initiating antigens; compared to immediately preceding titre for boosting antigens.
Brisbane = A/Brisbane/59/2007(H1N1)-like, component of the northern hemisphere 2008–09 and 2009–10 TIV.
California = A/California/07/2009(H1N1)-like, component of the northern hemisphere 2010–11 TIV.
doi:10.1371/journal.pone.0038929.t003
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strains and vaccine formulations (live, inactivated, trivalent,
quadrivalent, adjuvanted etc) would be worthwhile. Ultimately,
mouse studies are supportive but cannot alone be interpreted as
conclusive for human immune responses [50]. The main strength
of our findings, however, is the consistency across human and
animal studies, across manufacturer’s TIV products, across HI and
MN assays, and in this study under controlled experimental
conditions, suggesting the interactions we report are unlikely to
have been due to bias or chance alone. In that regard, they
warrant further detailed evaluation.
In conclusion, we highlight dominant Yamagata responses
previously shown for the first time in naı ¨ve children [4,5], and here
confirmed in mice regardless of the initiating lineage of influenza B
priming. If further confirmed, these findings have both scientific
and practical implications for influenza vaccine protection,
trivalent or quadrivalent, in young children. Further study across
additional seasons, antigens and products, including trivalent and
quadrivalent formulations, as well as epitope-specific and mech-
anistic investigations will be important to clarify the nature and
relevance of these immunologic interactions.
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